Drug firm Strides Shasun has received Establishment Inspection Report (EIR) from the US health regulator on closure of inspection of its R&D centre in Chennai.
"The company's Control Test Laboratory, which is part of its R&D centre in Chennai was inspected by the USFDA in August 2016 has received the Establishment Inspection Report (EIR), thereby confirming the closure of the inspection. The laboratory continues to be USFDA approved," Strides said in a BSE filing.
USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
Shares of Strides Shasun were trading at Rs 1,077 apiece, up 0.13 per cent, from its previous close on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
